References
- Silva H, Koski G, Whalen M, et al. A systems approach to enhance clinical research and medicines development. J Med Dev Sci. 2016;1(1):59–67.
- Smythe W, Kramer N. Investigational medicinal product (IMP) management. a comprehensive and practical guide to clinical trials. London (UK): Elsevier; 2017. p. 103–117.
- Nugent P, Duncan JN, Colagiovanni DB. Chapter 12 – the preparation of a preclinical dossier to support an investigational new drug (IND) application and first-in-human clinical trial. In: Faqi AS, editor. A comprehensive guide to toxicology in preclinical drug development. London (UK): Academic Press; 2013. p. 309–334.
- Van Norman GA. Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs. JACC Basic Transl Sci. 2016;1(3):170–179.
- Jandhyala R. The multiple stakeholder approach to real-world evidence (RWE) generation: observing multidisciplinary expert consensus on quality indicators of rare disease patient registries (RDRs). Curr Med Res Opin. 2021;37(7):1249–1257.
- Bothwell LE, Greene JA, Podolsky SH, et al. Assessing the gold standard-lessons from the history of RCTs. N Engl J Med. 2016;374(22):2175–2181.
- Logviss K, Krievins D, Purvina S. Characteristics of clinical trials in rare vs. common diseases: a register-based Latvian study. PLOS One. 2018;13(4):e0194494.
- Jandhyala R. Neutral theory: a conceptual framework for construct measurement in clinical research (Pre-print). 2020. DOI:10.13140/RG.2.2.33212.16008
- Jandhyala R. Neutral theory: applicability and neutrality of using generic health-related quality of life tools in diseases or conditions where specific tools are available. BMC Med Res Methodol. 2021;21(1):86.
- Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence – what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297.
- Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867–868.
- Girman CJ, Ritchey ME, Zhou W, et al. Considerations in characterizing real-world data relevance and quality for regulatory purposes: a commentary. Pharmacoepidemiol Drug Saf. 2019;28(4):439–442.
- Miksad RA, Abernethy AP. Harnessing the power of real-world evidence (RWE): a checklist to ensure regulatory-grade data quality. Clin Pharmacol Ther. 2018;103(2):202–205.
- Jandhyala R. A novel method for observing proportional group awareness and consensus of items arising from list-generating questioning. Curr Med Res Opin. 2020;36(5):883–893.
- Jandhyala R. Delphi, non-RAND modified Delphi, RAND/UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review. Curr Med Res Opin. 2020;36(11):1873–1887.
- Khandkar SH. Open coding. University of Calgary. 2009;23.
- Stemler S. An overview of content analysis. Practical Assessment Res Eval. 2000;7(1):17.
- Thompson D, Graff J, Critchlow C, et al. 21st Century Cures Act and the Future of RWE Generation. ISPOR 2018 Symposium. Baltimore (MD): Syneos Health; 2018.